BioSpace News Archive

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “company”) announces that effective immediately, Dr. George Garibaldi will serve on its Scientific Board of Advisors.

hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics.

Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.

Eclipse Bioinnovations today announced new research demonstrating the optimization of Eclipsebio’s industry-standard eCLIP technology to improve the study of RNA-binding protein interactomes, which promises to accelerate the study of human diseases caused by failed RNA processing.

The Diagnostic Ultra-portable X-ray for Space (DUXS) program achieved liftoff late last year by successfully obtaining medical diagnostic radiographic images in zero-gravity (Zero-G) conditions – including a re-creation of one of the first X-ray images ever taken by Nobel Prize winner Wilhelm Conrad Röntgen.

Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization (“CDMO”), announced today the appointment of David Tammaro as Chief Financial Officer.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the International patent application forward in the US, Europe, Canada and Australia.

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2023 following the close of regular trading on Tuesday, January 31, 2023.

ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard of care treatment for ST-elevation myocardial infarction (STEMI) patients.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 6, 2023.